Invivyd, Inc. (IVVD)
Automate Your Wheel Strategy on IVVD
With Tiblio's Option Bot, you can configure your own wheel strategy including IVVD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IVVD
- Rev/Share 0.306
- Book/Share 0.4517
- PB 1.6583
- Debt/Equity 0.0165
- CurrentRatio 1.5289
- ROIC -2.6745
- MktCap 89850789.0
- FreeCF/Share -1.1807
- PFCF -0.6348
- PE -0.6292
- Debt/Assets 0.0086
- DivYield 0
- ROE -1.6523
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in moderately to severely immunocompromised adults and adolescents (aged 12 or older) at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart.
Read More
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requests In contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled trials to evaluate safety, immunogenicity, and exploratory efficacy in relevant, modern Americans, against relevant, modern immune-evasive SARS-CoV-2 viruses, and over the long-term Invivyd plans to advance next generation COVID-19 mAbs to improve product scalability and system-friendliness while preserving strong anticipated mAb preventative efficacy; additional data on Invivyd's investigational mAb VYD2311 …
Read More
Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Invivyd, Inc. (NASDAQ:IVVD ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Katie Falzone - Senior Vice President, Finance Marc Elia - Chairman Tim Lee - Chief Commercial Officer Bill Duke - Chief Financial Officer Dr. Robert Allen - Chief Scientific Officer Dr. Mark Wingertzahn - Senior Vice President, Clinical Development Conference Call Participants Kyle Yang - Jefferies Luis Santos - H.C. Wainwright Operator Thank you for standing by.
Read More
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.38 per share a year ago.
Read More
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who are treating active measles and monitoring contacts and outbreaks have inquired directly to Invivyd about the possibility of accessing such a medicine, as there are no currently approved therapies for measles or for post-exposure prophylaxis. Measles monoclonal neutralizing antibody discovery efforts would join current Invivyd discovery programs for next-generation COVID-19, respiratory syncytial virus (RSV), and influenza mAbs designed to treat acute infection or provide a high-quality alternative to vaccination.
Read More
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights.
Read More
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain conditions and milestones are met.
Read More
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.
Read More
5 Stocks That More Than Doubled Halfway Through Q1
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
We highlight five stocks from different sectors that more than doubled halfway through the first quarter.
Read More
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Read More
About Invivyd, Inc. (IVVD)
- IPO Date 2021-08-06
- Website https://adagiotx.com
- Industry Biotechnology
- CEO Mr. William E. Duke Jr., M.B.A.
- Employees 99